Search

Displaying results 1411 - 1420 of 4692 in total
  1. Drug

    Iron

    go.drugbank.com/drugs/DB01592
    ApprovedInvestigational

    Iron is used to build up the blood in anemia.

  2. Drug

    Seliforant

    go.drugbank.com/drugs/DB15220
    Investigational

    Seliforant is under investigation in clinical trial NCT01260753 (Proof of Activity Study of UR-63325 in Allergic Rhinitis Induced by Nasal Challenge).

  3. Drug

    Iopromide

    go.drugbank.com/drugs/DB09156
    Approved

    [A260751] Approved by the FDA in 1995 and Health Canada in 1994 under the brand name ULTRAVIST, iopromide is used in radiological diagnosis, including, but not limited to, intra-arterial digital subtraction … It functions as a contrast agent by opacifying blood vessels in the flow path of the contrast agent, permitting radiographic visualization of the internal structures until significant hemodilution occurs

  4. Drug

    Benzquinamide

    go.drugbank.com/drugs/DB00767
    ApprovedWithdrawn

    The mechanism of action is not known, but presumably benzquinamide works via antagonism of muscarinic acetycholine receptors and histamine H1 receptors.

  5. Drug

    Meropenem

    go.drugbank.com/drugs/DB00760
    ApprovedInvestigational

    Meropenem exerts its action by penetrating bacterial cells readily and interfering with the synthesis of vital cell wall components, which leads to cell death. … The treatment aims to resolve infection-related symptoms and achieve negative urine culture, where the infections are proven or strongly suspected to be caused by susceptible bacteria.

  6. Drug

    Etryptamine

    go.drugbank.com/drugs/DB01546
    ApprovedIllicitWithdrawn

    αET is a stimulant and hallucinogen, but it is less stimulating and hallucinogenic than alpha-methyltryptamine, a closely related compound. … In 1993, the US Drug Enforcement Administration added αET to Schedule I of its Schedules of Controlled Substances, after an increasing incidence of its use as a recreational drug in the 1980's.

  7. Drug

    Crizotinib

    go.drugbank.com/drugs/DB08865
    ApprovedInvestigational

    [A250785] Crizotinib was approved by the FDA in 2011, and its use is accompanied by FDA-approved tests used to detect ALK and ROS1 rearrangements.[L42460] … [L42460] By targeting the echinoderm microtubule-associated protein-like 4 (EML4)-ALK fusion protein, crizotinib offers robust effectiveness in treating NSCLC in patients with this type of rearrangement

  8. Drug

    Tetrofosmin

    go.drugbank.com/drugs/DB11180
    Approved

    Tetrofosmin was developed to overcome the non-target uptake of radioligands by the generation of hetero-atomic compounds.

  9. Drug

    Alunacedase alfa

    go.drugbank.com/drugs/DB15736
    Investigational

    Alunacedase alfa is a recombinant and soluble glycosylated form of human ACE2. This recombinant version of the enzyme has antihypertensive and potential antineoplastic activities.

  10. Drug

    D-Cysteine

    go.drugbank.com/drugs/DB03201
    Experimental

    A thiol-containing non-essential amino acid that is oxidized to form CYSTINE.